ALX ONCOLOGY HOLDINGS INC Increase (Decrease) in Other Operating Assets
ALX ONCOLOGY HOLDINGS INC (ALXO) reported Increase (Decrease) in Other Operating Assets of -$307.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingAssets · last filed 2026-08-06
- ALX ONCOLOGY HOLDINGS INC increase (decrease) in other operating assets for the quarter ending 2026-06-30 was -$1.00K, a 100.22% decline year-over-year.
- ALX ONCOLOGY HOLDINGS INC increase (decrease) in other operating assets for the quarter ending 2026-03-31 was -$306.00K.
- ALX ONCOLOGY HOLDINGS INC increase (decrease) in other operating assets for the quarter ending 2025-12-31 was -$5.01M.
- ALX ONCOLOGY HOLDINGS INC increase (decrease) in other operating assets for the quarter ending 2025-09-30 was $5.26M.
- ALX ONCOLOGY HOLDINGS INC increase (decrease) in other operating assets for fiscal 2025 was $686.00K.
- ALX ONCOLOGY HOLDINGS INC increase (decrease) in other operating assets for fiscal 2024 was -$7.38M.
- ALX ONCOLOGY HOLDINGS INC increase (decrease) in other operating assets for fiscal 2023 was -$1.37M.
- ALX ONCOLOGY HOLDINGS INC increase (decrease) in other operating assets for fiscal 2022 was -$750.00K, a 107.75% decline from fiscal 2021.
| Period end | Increase (Decrease) in Other Operating Assets 3 month | Increase (Decrease) in Other Operating Assets 6 month | Increase (Decrease) in Other Operating Assets 9 month | Increase (Decrease) in Other Operating Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$307.00K 10-Q · filed 2026-08-06 | -$5.31M derived: sum of 3 quarters · filed 2026-08-06 | -$54.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$306.00K 10-Q · filed 2026-05-08 | -$5.31M derived: sum of 2 quarters · filed 2026-05-08 | -$53.00K derived: sum of 3 quarters · filed 2026-05-08 | $392.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$5.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $253.00K derived: sum of 2 quarters · filed 2026-03-09 | $698.00K derived: sum of 3 quarters · filed 2026-08-06 | $686.00K 10-K · filed 2026-03-09 |
| 2025-09-30 | $5.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $5.71M derived: sum of 2 quarters · filed 2026-08-06 | $5.69M 10-Q · filed 2025-11-07 | $488.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $445.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $433.00K 10-Q · filed 2026-08-06 | -$4.77M derived: sum of 3 quarters · filed 2026-08-06 | -$5.03M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$12.00K 10-Q · filed 2026-05-08 | -$5.22M derived: sum of 2 quarters · filed 2026-05-08 | -$5.47M derived: sum of 3 quarters · filed 2026-05-08 | -$7.24M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | -$5.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$5.46M derived: sum of 2 quarters · filed 2026-03-09 | -$7.23M derived: sum of 3 quarters · filed 2026-03-09 | -$7.38M 10-K · filed 2026-03-09 |
| 2024-09-30 | -$255.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$2.02M derived: sum of 2 quarters · filed 2025-11-07 | -$2.17M 10-Q · filed 2025-11-07 | $679.00K derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-06-30 | -$1.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$1.92M 10-Q · filed 2025-08-12 | $934.00K derived: sum of 3 quarters · filed 2026-03-09 | $144.00K derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-03-31 | -$149.00K 10-Q · filed 2025-05-08 | $2.70M derived: sum of 2 quarters · filed 2026-03-09 | $1.91M derived: sum of 3 quarters · filed 2026-03-09 | -$338.00K derived: sum of 4 quarters · filed 2026-03-09 |
| 2023-12-31 | $2.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $2.06M derived: sum of 2 quarters · filed 2026-03-09 | -$189.00K derived: sum of 3 quarters · filed 2026-03-09 | -$1.37M 10-K · filed 2026-03-09 |
| 2023-09-30 | -$790.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$3.04M derived: sum of 2 quarters · filed 2024-11-07 | -$4.21M 10-Q · filed 2024-11-07 | -$5.23M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | -$2.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$3.42M 10-Q · filed 2024-08-12 | -$4.44M derived: sum of 3 quarters · filed 2025-03-06 | -$4.49M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | -$1.18M 10-Q · filed 2024-05-09 | -$2.19M derived: sum of 2 quarters · filed 2025-03-06 | -$2.25M derived: sum of 3 quarters · filed 2025-03-06 | -$2.24M derived: sum of 4 quarters · filed 2025-03-06 |
| 2022-12-31 | -$1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$1.07M derived: sum of 2 quarters · filed 2025-03-06 | -$1.07M derived: sum of 3 quarters · filed 2025-03-06 | -$750.00K 10-K · filed 2025-03-06 |
| 2022-09-30 | -$51.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$50.00K derived: sum of 2 quarters · filed 2023-11-13 | $267.00K 10-Q · filed 2023-11-13 | -$704.00K derived: sum of 4 quarters · filed 2024-03-07 |
| 2022-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $318.00K 10-Q · filed 2023-08-10 | -$653.00K derived: sum of 3 quarters · filed 2024-03-07 | $962.00K derived: sum of 4 quarters · filed 2024-03-07 |
| 2022-03-31 | $317.00K 10-Q · filed 2023-05-11 | -$654.00K derived: sum of 2 quarters · filed 2024-03-07 | $961.00K derived: sum of 3 quarters · filed 2024-03-07 | $9.42M derived: sum of 4 quarters · filed 2024-03-07 |
| 2021-12-31 | -$971.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $644.00K derived: sum of 2 quarters · filed 2024-03-07 | $9.10M derived: sum of 3 quarters · filed 2024-03-07 | $9.68M 10-K · filed 2024-03-07 |
| 2021-09-30 | $1.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $10.07M derived: sum of 2 quarters · filed 2022-11-08 | $10.65M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $8.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $9.04M 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | $583.00K 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | $10.00K 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |